According to the pharmaceutical outsourcing services provider, the announcement follows an initial capital investment in specialist cryogenic storage in Rockford announced in November of last year.
Upon completion, the expanded facility will feature larger-scale specialized storage to accommodate two- and five-milliliter vials in addition to blood bags.
Brian Keesee, General Manager, US Clinical Services at PCI explained the enhanced capability in the US is the latest in a series of major investments to support clinical trial supply.
“This current investment will support considerable further business growth in this segment,” Keesee told Outsourcing-Pharma.com, adding that the investment enables PCI “to meet the growing need of the pharmaceutical and biotech market for large-scale, high quality storage of temperature-sensitive products and breakthrough therapies.”
The expansion follows a similar 400% storage capacity gain at PCI’s Bridgend, UK-based site. The site now features a purpose-built and dedicated -40°C facility in addition to expanded frozen storage at -80°C.